Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 231-669-9 | CAS number: 7681-53-0
Endpoint summary
Administrative data
Description of key information
Key value for chemical safety assessment
Skin sensitisation
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed (not sensitising)
- Additional information:
One study is recorded for this endpoint and was chosen as a key study. The delayed contact hypersensitivity of sodium hypophosphite was assessed using the murine Local Lymph Node Assay . This study was conducted in compliance with the principles of Good Laboratory Practices and performed according to the OECD guideline 429 and the EU Method B.42.
Results showed no cutaneous reactions and no increase in ear thickness. No lymphoproliferation was noted. Over the range of sodium hypophosphite tested concentrations (2.5% to the maximal practicable concentration of 50%), the Stimulation Index (SI) varied from 1.01 to 1.79.
Under these test conditions, sodium hypophosphite was considered as not sensitising.
Migrated from Short description of key information:
The potential of sodium hypophosphite to induce delayed contact hypersensitivity was investigated using the murine Local Lymph Node Assay (LLNA)(OECD 429 , EU B 42 method, GLP) . The test item was found to be non-sensitising.
Respiratory sensitisation
Endpoint conclusion
- Additional information:
- Migrated from Short description of key information:
There is no reported case of respiratory sensitisation in humans.
Justification for classification or non-classification
Skin sensitisation:
In accordance with column 2 of REACH annex VII point 8.3, the murine Local Lymph Node Assay (LLNA) (OECD guideline 429) is the first-choice method for in vivo testing of skin sensitisation. Hence, the results of the reported study were used as a basis for classification. According to the criteria laid down in EU regulation (EC) n°1272/2008 (CLP) and EU Directive 67/548/EEC, sodium hypophosphite is not classified for skin sensitisation.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
